Pfizer Inc (PFE)
28.09
-0.21
(-0.74%)
USD |
NYSE |
Nov 01, 16:00
28.10
+0.01
(+0.04%)
After-Hours: 20:00
Pfizer Enterprise Value: 221.03B for Nov. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 01, 2024 | 221.03B |
| October 31, 2024 | 222.22B |
| October 30, 2024 | 223.47B |
| October 29, 2024 | 223.13B |
| October 28, 2024 | 225.39B |
| October 25, 2024 | 223.07B |
| October 24, 2024 | 224.15B |
| October 23, 2024 | 225.39B |
| October 22, 2024 | 225.28B |
| October 21, 2024 | 225.79B |
| October 18, 2024 | 227.43B |
| October 17, 2024 | 227.72B |
| October 16, 2024 | 229.98B |
| October 15, 2024 | 228.68B |
| October 14, 2024 | 226.64B |
| October 11, 2024 | 227.09B |
| October 10, 2024 | 228.11B |
| October 09, 2024 | 232.93B |
| October 08, 2024 | 227.21B |
| October 07, 2024 | 227.32B |
| October 04, 2024 | 223.81B |
| October 03, 2024 | 222.45B |
| October 02, 2024 | 223.98B |
| October 01, 2024 | 224.32B |
| September 30, 2024 | 225.85B |
| Date | Value |
|---|---|
| September 27, 2024 | 226.70B |
| September 26, 2024 | 226.02B |
| September 25, 2024 | 225.79B |
| September 24, 2024 | 229.02B |
| September 23, 2024 | 227.94B |
| September 20, 2024 | 228.57B |
| September 19, 2024 | 229.93B |
| September 18, 2024 | 230.44B |
| September 17, 2024 | 230.89B |
| September 16, 2024 | 232.25B |
| September 13, 2024 | 227.72B |
| September 12, 2024 | 227.09B |
| September 11, 2024 | 229.93B |
| September 10, 2024 | 230.38B |
| September 09, 2024 | 228.51B |
| September 06, 2024 | 223.69B |
| September 05, 2024 | 223.41B |
| September 04, 2024 | 222.73B |
| September 03, 2024 | 222.22B |
| August 30, 2024 | 226.24B |
| August 29, 2024 | 224.60B |
| August 28, 2024 | 224.77B |
| August 27, 2024 | 225.17B |
| August 26, 2024 | 225.73B |
| August 23, 2024 | 225.62B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
167.23B
Minimum
Dec 14 2023
352.78B
Maximum
Dec 16 2021
245.85B
Average
241.39B
Median
Oct 13 2021
Enterprise Value Benchmarks
| Amgen Inc | 222.98B |
| Johnson & Johnson | 400.99B |
| Eli Lilly and Co | 805.11B |
| Viking Therapeutics Inc | 7.191B |
| Moderna Inc | 12.51B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 4.465B |
| Revenue (Quarterly) | 17.70B |
| Total Expenses (Quarterly) | 12.42B |
| EPS Diluted (Quarterly) | 0.78 |
| Gross Profit Margin (Quarterly) | 70.27% |
| Profit Margin (Quarterly) | 25.22% |
| Earnings Yield | 2.63% |
| Operating Earnings Yield | 6.12% |
| Normalized Earnings Yield | 5.526 |